Innovent Biologics is a biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines for cancer and other major diseases. Founded in 2011, the company has developed a broad therapeutic portfolio spanning oncology, cardiovascular and metabolic diseases, autoimmune diseases, and ophthalmology, supported by integrated capabilities from drug discovery and clinical development through manufacturing and commercialization.

Innovent has launched 18 products and continues to advance a pipeline of late- and early-stage therapies, including next-generation oncology programs and medicines addressing chronic and specialty diseases. The company is also expanding its global clinical-development capabilities and has established partnerships with more than 30 healthcare and biotechnology organizations worldwide, including Takeda, Lilly, Roche, Sanofi, and others, as it develops medicines for both China and international markets.